Companies Q32 Bio Inc.
Q32 Bio (FIXX): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Q32 Bio Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask; press Download and a copy goes to your email too. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $6,003,238FY2024
- $1,558,870FY2025
CEO total pay was $1,558,870 in fiscal 2025, down from $6,003,238 in fiscal 2024.
FY2025: salary $645,600 · bonus $0 · stock awards $335,280 · option awards $220,792
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Jodie Morrison | $645,600 | $0 | $335,280 | $220,792 | $355,080 | $0 | $2,118 | $1,558,870 |
| Chief Executive Officer and Director | ||||||||
| Lee Kalowski | 565,000 | 0 | 135,255 | 59,122 | 226,000 | 0 | 1,770 | 987,147 |
| Chief Financial Officer and President | ||||||||
| Shelia Violette | 455,000 | 0 | 95,250 | 37,312 | 182,000 | 0 | 4,884 | 774,446 |
| Chief Scientific Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Jodie Morrison | $1,558,870 | $6,003,238 | — | ↓ −4,444,368 |
| Lee Kalowski | 987,147 | 2,854,009 | — | ↓ −1,866,862 |
| Shelia Violette | 774,446 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our executive compensation program consists of a combination of base salary, non-equity incentive compensation and long-term equity incentives designed to reflect competitive levels of compensation for comparable positions in the market, including among peer companies, while considering historical compensation levels, individual performance, and the achievement of corporate objectives.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon plc |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Lee Kalowski | RSU | 2025-02-24 | — | — | 177,325 | — | $135,255 |
| Jodie Morrison | RSU | 2025-02-24 | — | — | 439,560 | — | 335,280 |
| Shelia Violette | RSU | 2025-02-24 | — | — | 124,875 | — | 95,250 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Lee Kalowski | $135,255 | $0 | $0 | 0.0% |
| Jodie Morrison | 335,280 | 0 | 0 | 0.0% |
| Shelia Violette | 95,250 | 0 | 0 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Jodie Morrison | Option | 7,745 | 2.54 | — |
| Shelia Violette | RSU | 28,125 | — | 96,750 |
| Jodie Morrison | Option | 28,628 | 2.54 | — |
| Shelia Violette | Option | 31,733 | 2.54 | — |
| Jodie Morrison | Option | 34,991 | 2.54 | — |
| Lee Kalowski | RSU | 39,938 | — | 137,387 |
| Lee Kalowski | Option | 73,941 | 2.54 | — |
| Jodie Morrison | RSU | 99,000 | — | 340,560 |
| Jodie Morrison | Option | 221,876 | 2.54 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Mark IwickiIndependent · Board Chair · Audit · Compensation (Chair) · Not standing for re-election | $95,000 | — | $134,443 | — | — | $229,443 |
| Kathleen LaPorteIndependent · Audit (Chair) · Nominating and Corporate Governance | 64,000 | — | 120,096 | — | — | 184,096 |
| Bill Lundberg, M.DIndependent · Compensation · Not standing for re-election | 56,000 | — | 123,500 | — | — | 179,500 |
| Mary ThistleIndependent · Audit · Nominating and Corporate Governance (Chair) · Not standing for re-election | 59,500 | — | 118,237 | — | — | 177,737 |
| David Grayzel, M.DIndependent · Research and Development · Not standing for re-election | 45,000 | — | 121,024 | — | — | 166,024 |
| Isaac Manke, Ph.DIndependent · Compensation · Not standing for re-election | 46,000 | — | 119,003 | — | — | 165,003 |
| Arthur Tzianabos, Ph.DNot independent · Research and Development | 45,000 | — | 118,237 | — | — | 163,237 |
| Diyong XuIndependent · Nominating and Corporate Governance · Not standing for re-election | 45,000 | — | 118,237 | — | — | 163,237 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $114,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 9,500 / 6,000 / 5,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $455,500 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $455,500 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Q32 Bio as a peer
Companies that benchmark against FIXX
No companies currently name FIXX as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Q32 Bio Inc. | 2025 | Jodie Morrison | $645,600 | $335,280 | $220,792 | $355,080 | $1,558,870 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (18 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Jodie Morrison. DEF 14A, filed 2026-04-30. Section “Executive Compensation” · page 25. As printed: 1,558,870. View filing ↗
- Section 01, Lee Kalowski. DEF 14A, filed 2026-04-30. Section “Executive Compensation” · page 25. As printed: 987,147. View filing ↗
- Section 01, Shelia Violette. DEF 14A, filed 2026-04-30. Section “Executive Compensation” · page 25. As printed: 774,446. View filing ↗
- Section 03, Lee Kalowski RSU. DEF 14A, filed 2026-04-30. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Jodie Morrison RSU. DEF 14A, filed 2026-04-30. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Shelia Violette RSU. DEF 14A, filed 2026-04-30. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 08, Mark Iwicki. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 229,443. View filing ↗
- Section 08, Kathleen LaPorte. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 184,096. View filing ↗
- Section 08, Bill Lundberg, M.D. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 179,500. View filing ↗
- Section 08, Mary Thistle. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 177,737. View filing ↗
- Section 08, David Grayzel, M.D. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 166,024. View filing ↗
- Section 08, Isaac Manke, Ph.D. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 165,003. View filing ↗
- Section 08, Arthur Tzianabos, Ph.D. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 163,237. View filing ↗
- Section 08, Diyong Xu. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 163,237. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 455,500 + equity 0 + all other 0 = 455,500, summed across the director compensation table rows.
- Q32 Bio Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Q32 Bio Inc.'s own proxy. As printed: 1,558,870. View filing ↗